|
JP2001507215A
(ja)
*
|
1997-01-16 |
2001-06-05 |
サイテル コーポレイション |
組換え糖タンパク質のインビトロでの実用的なシアリル化
|
|
US6689604B1
(en)
|
1998-03-20 |
2004-02-10 |
National Research Council Of Canada |
Lipopolysaccharide α-2,3 sialyltransferase of Campylobacter jejuni and its uses
|
|
DK1137789T3
(da)
|
1998-12-09 |
2010-11-08 |
Phyton Holdings Llc |
Fremgangsmåde til fremstilling af et glycoprotein med glycosylering af human type
|
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
|
DE60044858D1
(de)
|
1999-10-26 |
2010-09-30 |
Stichting Dienst Landbouwkundi |
Säugetierartige Glykosylierung in Pflanzen
|
|
JP2004528001A
(ja)
*
|
2000-05-12 |
2004-09-16 |
ネオーズ テクノロジーズ， インコーポレイテッド |
インビトロにおけるフコシル化組換えグリコペプチド
|
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
|
DK1356068T3
(en)
|
2001-01-19 |
2015-02-16 |
Phyton Holdings Llc |
PROCESS FOR THE PRODUCTION OF secretory glycoprotein with HUMAN TYPE SUGAR CHAIN FOR USING A PLANT CELL
|
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
ES2411007T3
(es)
|
2001-10-10 |
2013-07-04 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
|
MEP38608A
(en)
*
|
2001-10-22 |
2011-02-10 |
Merck Serono Sa |
Gonadotrophins for folliculogenesis
|
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
|
AU2002351199A1
(en)
|
2001-11-28 |
2003-06-10 |
Neose Technologies, Inc. |
Glycoprotein remodeling using endoglycanases
|
|
CN1665934B
(zh)
|
2002-03-19 |
2010-05-26 |
国际植物研究所 |
GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达
|
|
CN101613705A
(zh)
|
2002-03-19 |
2009-12-30 |
国际植物研究所 |
在植物中优化聚糖生成
|
|
DE60336555D1
(de)
|
2002-06-21 |
2011-05-12 |
Novo Nordisk Healthcare Ag |
Pegylierte glykoformen von faktor vii
|
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
|
EP1552298A4
(en)
*
|
2002-07-01 |
2006-11-08 |
Kenneth S Warren Inst Inc |
RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
|
|
AU2003301332B2
(en)
*
|
2002-10-17 |
2008-06-12 |
Pharming Intellectual Property B.V. |
Protein modification
|
|
CL2003002461A1
(es)
|
2002-11-27 |
2005-01-07 |
Dow Chemical Company Agroscien |
Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
|
|
NZ542094A
(en)
|
2003-03-14 |
2008-12-24 |
Neose Technologies Inc |
Branched polymer conjugates comprising a peptide and water-soluble polymer chains
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
EP1613261A4
(en)
*
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
|
PL1615945T3
(pl)
|
2003-04-09 |
2012-03-30 |
Ratiopharm Gmbh |
Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
|
|
JP2007523630A
(ja)
*
|
2003-05-09 |
2007-08-23 |
ネオス テクノロジーズ インコーポレイテッド |
ヒト成長ホルモングリコシル化突然変異体の組成と調合法
|
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
|
WO2005032467A2
(en)
*
|
2003-09-29 |
2005-04-14 |
Warren Pharmaceuticals, Inc. |
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
|
|
US7842661B2
(en)
*
|
2003-11-24 |
2010-11-30 |
Novo Nordisk A/S |
Glycopegylated erythropoietin formulations
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
EP1694347B1
(en)
*
|
2003-11-24 |
2013-11-20 |
BioGeneriX AG |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
NZ548123A
(en)
|
2004-01-08 |
2010-05-28 |
Novo Nordisk As |
O-linked glycosylation of peptides
|
|
AU2005208897B2
(en)
*
|
2004-01-26 |
2011-05-19 |
Ratiopharm Gmbh |
Branched polymeric sugars and nucleotides thereof
|
|
KR20070008645A
(ko)
|
2004-05-04 |
2007-01-17 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
|
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
|
US20090292110A1
(en)
*
|
2004-07-23 |
2009-11-26 |
Defrees Shawn |
Enzymatic modification of glycopeptides
|
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
|
JP4812625B2
(ja)
*
|
2004-10-18 |
2011-11-09 |
日本たばこ産業株式会社 |
糖転移酵素の酵素活性を向上させる方法
|
|
WO2006050247A2
(en)
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
JP2008526864A
(ja)
*
|
2005-01-06 |
2008-07-24 |
ネオス テクノロジーズ インコーポレイテッド |
糖断片を用いる糖結合
|
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
US20100143969A1
(en)
*
|
2005-03-24 |
2010-06-10 |
Neose Technologies, Inc. |
Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
|
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
EP2975135A1
(en)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
US20110003744A1
(en)
*
|
2005-05-25 |
2011-01-06 |
Novo Nordisk A/S |
Glycopegylated Erythropoietin Formulations
|
|
FI20055398A0
(fi)
|
2005-07-08 |
2005-07-08 |
Suomen Punainen Risti Veripalv |
Menetelmä solupopulaatioiden evaluoimiseksi
|
|
MX2008002395A
(es)
*
|
2005-08-19 |
2008-03-18 |
Neose Technologies Inc |
Factor vii y factor viia glicopegilados.
|
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007028106A2
(en)
|
2005-08-31 |
2007-03-08 |
Centocor, Inc. |
Host cell lines for production of antibody constant region with enhanced effector function
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
FR2901707B1
(fr)
*
|
2006-05-31 |
2017-09-29 |
Lab Francais Du Fractionnement |
Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
|
|
AR078117A1
(es)
|
2006-06-20 |
2011-10-19 |
Protech Pharma S A |
Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
|
|
EP2049144B8
(en)
|
2006-07-21 |
2015-02-18 |
ratiopharm GmbH |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
FR2904558B1
(fr)
*
|
2006-08-01 |
2008-10-17 |
Lab Francais Du Fractionnement |
"composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
|
|
EP2054521A4
(en)
*
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
|
|
ES2655734T3
(es)
|
2006-10-04 |
2018-02-21 |
Novo Nordisk A/S |
Glicopéptidos y azúcares pegilados unidos a glicerol
|
|
JP2010512306A
(ja)
*
|
2006-10-27 |
2010-04-22 |
ザ ロックフェラー ユニバーシティー |
抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
|
|
FI20075030A0
(fi)
*
|
2007-01-18 |
2007-01-18 |
Suomen Punainen Risti Veripalv |
Menetelmä solujen modifioimiseksi
|
|
HRP20130382T1
(hr)
|
2007-04-03 |
2013-05-31 |
Biogenerix Ag |
Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
|
|
WO2008125972A2
(en)
|
2007-04-17 |
2008-10-23 |
Plant Research International B.V. |
Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
|
|
JP6050927B2
(ja)
*
|
2007-04-26 |
2016-12-21 |
シーエヌジェイ ホールディングス，インコーポレイテッド |
高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
|
|
CA2690611C
(en)
|
2007-06-12 |
2015-12-08 |
Novo Nordisk A/S |
Improved process for the production of nucleotide sugars
|
|
US7968811B2
(en)
*
|
2007-06-29 |
2011-06-28 |
Harley-Davidson Motor Company Group, Inc. |
Integrated ignition and key switch
|
|
MX2010002448A
(es)
|
2007-08-27 |
2010-10-04 |
Biogenerix Ag |
Formulacion liquida del g-csf conjugado.
|
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
|
PL2257311T3
(pl)
|
2008-02-27 |
2014-09-30 |
Novo Nordisk As |
Koniugaty cząsteczek czynnika VIII
|
|
TWI488640B
(zh)
|
2008-04-16 |
2015-06-21 |
菲瑞茵國際中心股份有限公司 |
藥學製劑
|
|
EP2166085A1
(en)
|
2008-07-16 |
2010-03-24 |
Suomen Punainen Risti Veripalvelu |
Divalent modified cells
|
|
ES2805964T3
(es)
|
2008-10-29 |
2021-02-16 |
Janssen Biotech Inc |
Composiciones de galactosa alfa (1-3) galactosa
|
|
CN102812039B
(zh)
|
2010-02-16 |
2016-01-20 |
诺沃—诺迪斯克有限公司 |
缀合蛋白质
|
|
DK2762489T3
(en)
|
2011-10-01 |
2018-07-02 |
Glytech Inc |
GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
|
|
US10265388B2
(en)
|
2012-02-21 |
2019-04-23 |
Cytonics Corporation |
Systems, compositions, and methods for transplantation
|
|
EP2877589B1
(en)
|
2012-07-26 |
2024-03-06 |
Momenta Pharmaceuticals, Inc. |
Glycoproteins with anti-inflammatory properties
|
|
SG11201507769SA
(en)
|
2013-03-29 |
2015-10-29 |
Glytech Inc |
Polypeptide having sialylated sugar chains attached thereto
|
|
WO2014186310A1
(en)
|
2013-05-13 |
2014-11-20 |
Momenta Pharmaceuticals, Inc. |
Methods for the treatment of neurodegeneration
|
|
AU2014312249A1
(en)
|
2013-08-28 |
2016-03-24 |
Cytonics Corporation |
Systems, compositions, and methods for transplantation and treating conditions
|
|
WO2015057622A1
(en)
|
2013-10-16 |
2015-04-23 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
US10889631B2
(en)
|
2014-11-20 |
2021-01-12 |
Cytonics Corporation |
Therapeutic variant alpha-2-macroglobulin compositions
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
JP6651548B2
(ja)
|
2015-05-22 |
2020-02-19 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォン・ヴィルブランド因子を製造するための方法
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
IL272987B
(en)
|
2017-09-04 |
2022-08-01 |
89Bio Ltd |
fgf-21 mutant peptide conjugates and uses thereof
|
|
US20220251619A1
(en)
*
|
2019-03-29 |
2022-08-11 |
Agency For Science, Technology And Research |
Method of Sialylating a Protein
|